KP-1461

KP-1461 is an experimental antiviral drug developed for the treatment of HIV/AIDS. It is a potent, non-chain-terminating mutagenic deoxyribonucleoside analogue and acts as an oral prodrug of KP-1212. The drug introduces continual mutations into HIV during viral replication by reverse transcriptase (RT), a process known as selective viral mutagenesis or lethal mutagenesis. Unlike traditional nucleoside reverse transcriptase inhibitors (NRTIs) that terminate DNA chain elongation, KP-1461 incorporates into the viral genome and pairs with multiple bases due to its modified base structure. This leads to an increased mutation rate in the virus's genetic material; when the accumulation of mutations exceeds a certain threshold, it results in loss of viral viability and potential eradication of the virus. Clinical studies have shown that while KP-1461 was generally well tolerated in humans, significant antiretroviral activity was not observed in short-term trials[1][3][5][6]. The drug was initially developed by Koronis Pharmaceuticals[8].

Other names

815588-85-3UNII-3PEN569TJPUNII3PEN569TJPUNII 3PEN569TJP